JB Chemicals & Pharmaceuticals has received USFDA approval for its Supplementary Abbreviated New Drug Application (sANDA) for Atenolol Tablets USP 25 mg. 50 mg. and 100 mg. (anti-hypertensive) manufactured using Company’s own bulk drug (API). The company had initiated this change as a part of its plan to gradually backward integrate US formulations business. This approval is expected to boost company’s US sales.
The company could not commercialize this formulation earlier due to problems associated with external API supplier. This approval will help company supply these formulations with its own API. The company plans to commercialize this product in the next quarter. Currently, the market for this product in US is about $70 million. The company is focused on US business and this approval will help grow its exports.
JB Chemicals & Pharmaceuticals (JBCPL) is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: